Kiniksa Collaborated with Huadong Medicine to Develop and Commercialize Arcalyst and Mavrilimumab for Autoimmune and Inflammatory Diseases
Shots:
- Kiniksa to receive $22M up front including $12M for the territory license of rilonacept and $10M for mavrilimumab and is eligible to receive ~$640M in development, regulatory and sales-based milestones along with royalties
- Huadong Medicine will get an exclusive right & will be responsible for the development and commercialization of Arcalyst and mavrilimumab in the Asia Pacific region including Greater China, South Korea, Australia, and 18 other countries (Ex-Japan)
- Kiniksa will retain development and commercialization rights to the licensed products outside the territory. Arcalyst received the BTD & ODD from the US FDA for the treatment of recurrent pericarditis
Ref: Kiniksa | Image: Linkedin
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com